L
Ljupco Veskovski
Researcher at University of Gothenburg
Publications - 4
Citations - 708
Ljupco Veskovski is an academic researcher from University of Gothenburg. The author has contributed to research in topics: Multiple myeloma & Melphalan. The author has an hindex of 2, co-authored 4 publications receiving 629 citations. Previous affiliations of Ljupco Veskovski include Sahlgrenska University Hospital.
Papers
More filters
Journal ArticleDOI
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial
Jesús F. San-Miguel,V. Hungria,Sung-Soo Yoon,Meral Beksac,Meletios A. Dimopoulos,Ashraf Elghandour,Wiesław Wiktor Jędrzejczak,Andreas Günther,Thanyaphong Na Nakorn,Noppadol Siritanaratkul,Paolo Corradini,Suporn Chuncharunee,Je-Jung Lee,Robert L. Schlossman,Tatiana Shelekhova,Kwee Yong,Daryl Tan,Tontanai Numbenjapon,Jamie Cavenagh,Jian Hou,Richard Leblanc,Hareth Nahi,Lugui Qiu,Hans Salwender,Stefano Pulini,Philippe Moreau,Krzysztof Warzocha,Darrell White,Joan Bladé,Wenming Chen,Javier de la Rubia,Peter Gimsing,Sagar Lonial,Jonathan L. Kaufman,Enrique M. Ocio,Ljupco Veskovski,Sang Kyun Sohn,Ming Chung Wang,Jae Hoon Lee,Hermann Einsele,Monika Sopala,Claudia Corrado,Bourras Rezki Bengoudifa,Florence Binlich,Paul G. Richardson +44 more
TL;DR: Panobinostat is a potent oral pan-deacetylase inhibitor that in preclinical studies has synergistic anti-myeloma activity when combined with bortezomib and dexamethasone and the proportion of patients achieving an overall response did not differ between treatment groups.
Journal ArticleDOI
Melphalan 100 mg/m2 with stem cell support as first relapse treatment is safe and effective for myeloma patients with long remission after autologous stem cell transplantation
Cecilie Blimark,Ljupco Veskovski,Jan Westin,Stig Rödjer,Mats Brune,Martin Hjorth,Erik Holmberg,Per-Ola Andersson,Ulf-Henrik Mellqvist +8 more
TL;DR: As the goal for the treatment for relapsed myeloma should be disease control while maintaining quality of life, lower doses of melphalan might be preferable.
Journal ArticleDOI
Serum Metabolomic Profiling Correlated with ISS and Clinical Outcome for Multiple Myeloma Patients Treated with High-dose Melphalan and Autologous Stem Cell Transplantation.
Ljupco Veskovski,Per-Ola Andersson,Ingemar Turesson,Daniel Malmodin,Anders Pedersen,Ulf-Henrik Mellqvist +5 more
TL;DR: In this paper, the authors used proton nuclear magnetic resonance (1H-NMR) spectroscopy to study the serum metabolomic profile of multiple myeloma (MM) patients and its relationship to clinical characteristics and patient outcome.
Journal ArticleDOI
Sequence variation at the MTHFD1L-AKAP12 and FOPNL loci does not influence multiple myeloma survival in Sweden
Mina Ali,Konstantinos Lemonakis,Anna-Karin Wihlborg,Ljupco Veskovski,Ingemar Turesson,Ulf-Henrik Mellqvist,Urban Gullberg,Markus Hansson,Björn Nilsson,Björn Nilsson +9 more
TL;DR: Looking for further support of the MTHFDL1-AKAP12 and FOPLN loci in a Swedish study population found that patients diagnosed with MM between 2005 and 2015 had been previously genotyped in genome-wide association studies using population-based samples from the Swedish Registry.